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Abstract
The human 1p36 region is deleted in many different types of tumors, and so it probably harbors one or more tumor
suppressor genes. In a Belgian neuroblastoma patient, a constitutional balanced translocation t(1;17)(p36.2;q11.2) may have
led to the development of the tumor by disrupting or activating a gene. Here, we report the cloning of both translocation
breakpoints and the identification of a novel gene that is disrupted by this translocation. This gene, named NBPF1 for
Neuroblastoma BreakPoint Family member 1, belongs to a recently described gene family encoding highly similar proteins,
the functions of which are unknown. The translocation truncates NBPF1 and gives rise to two chimeric transcripts of NBPF1
sequences fused to sequences derived from chromosome 17. On chromosome 17, the translocation disrupts one of the
isoforms of ACCN1, a potential glioma tumor suppressor gene. Expression of the NBPF family in neuroblastoma cell lines is
highly variable, but it is decreased in cell lines that have a deletion of chromosome 1p. More importantly, expression
profiling of the NBPF1 gene showed that its expression is significantly lower in cell lines with heterozygous NBPF1 loss than
in cell lines with a normal 1p chromosome. Meta-analysis of the expression of NBPF and ACCN1 in neuroblastoma tumors
indicates a role for the NBPF genes and for ACCN1 in tumor aggressiveness. Additionally, DLD1 cells with inducible NBPF1
expression showed a marked decrease of clonal growth in a soft agar assay. The disruption of both NBPF1 and ACCN1 genes
in this neuroblastoma patient indicates that these genes might suppress development of neuroblastoma and possibly other
tumor types.
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Introduction
Neuroblastoma, a tumor derived from pluripotent neuroblasts,
is the most frequent extracranial solid malignancy of childhood. It
is remarkably heterogeneous both clinically and biologically, as
there is a large variation in tumor progression depending on the
age of the patient at the time of diagnosis and the tumor stage [1].
Different genetic abnormalities are frequently observed in
primary neuroblastoma tumors and their derivative cell lines.
The most frequent aberration is the unbalanced gain of 17q, often
due to translocation of the 17q segment to other chromosomes,
combined with retention of two copies of the normal chromosome
17. One of the most common translocation partners for the 17q
fragment is chromosome 1p, indicating that this translocation
confers a selective advantage on cells by disrupting or activating
certain genes [2,3]. As the translocation breakpoints are scattered
on chromosomes 1 and 17, there is little evidence for a gene-
specific inactivation [4].
Amplification of the proto-oncogene MYCN, which occurs in
about one quarter of all neuroblastomas [1], is correlated with
poor prognosis [5]. Several studies have shown a strong correlation
between MYCN amplification and deletion of the short arm of
chromosome 1 [6], another frequent abnormality in neuroblasto-
mas. Other deletions frequently affect chromosomes 3p and 11q
[1] and hint at the presence of tumor suppressor genes (TSGs) in
these chromosomal regions.
Previously, we described a de novo, apparently balanced,
constitutional translocation t(1;17)(p36.2;q11.2) in a neuroblasto-
ma patient [7]. According to Knudson’s two-hit hypothesis,
constitutional deletions and translocations in patients with specific
tumors are often the first indicators of the presence of TSGs.
Several lines of evidence lead to the hypothesis that the 1p36 locus
harbors one or more TSGs for neuroblastoma. Introduction of the
short arm of chromosome 1 in the neuroblastoma cell line NGP
results in a differentiated phenotype [8], providing experimental
evidence for this hypothesis. Furthermore, constitutional deletions
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or translocations affecting the 1p36 region have been described in
other neuroblastoma patients [9,10]. Several other tumor types,
such as breast cancer, malignant melanoma and colorectal cancer,
are also characterized by frequent deletions or translocations of
1p36 [11]. In several types of tumors, including neuroblastoma,
the shortest regions of overlap for 1p deletions partly coincide,
indicating that the same TSGs may be implicated in different types
of tumors [12]. A number of strong candidate TSGs were recently
reported for 1p, including the CHD5 gene [13] and the
microRNA-34a [14]. However, deletions in chromosome 1p36
are often very large in neuroblastoma [15], and it is likely that
defects in more than one gene may contribute to the malignant
phenotype. Expression profiling showed that expression levels of
some genes located in the 1p35-36 region were decreased in
neuroblastoma tumors and cell lines with 1p deletion as compared
to 1p-normal samples [16,17]. Consequently, it was proposed that
the underlying reason for the frequent deletion of this region in
neuroblastoma is the decreased expression of several TSGs located
in the 1p36 region and not the inactivation of one single classical
TSG.
Methods
Probe generation
We previously described a cosmid contig spanning the
chromosome 17 breakpoint [18]. Nine regions lacking repetitive
elements were chosen as probes for Southern analysis and
amplified by PCR using PAC RPCI-1 880L8 as template. Probe
6, which is localized on the cosmid contig (GenBank Acc Nu
AF148647) from position 36,914 to 37,391, was amplified with
primers 59-TCCCAAAAGGCCAGTTTCACAC-39 and 59-
TCTGCAGGCGTCTCATCTCAAC-39. Probe 9 is located from
position 38,018 to 38,584, and was amplified with primers 59-
GTTGTACCCCCTTGACTTCA-39 and 59-GTGCCCAG-
CAGGAGATTCAAT-39.
Southern blotting
Genomic DNA from normal human placenta, the Chinese
hamster ovary cell line A/3, and somatic cell hybrids 32-7A and
32-2F53VIII [7] was extracted using standard procedures. DNA
was digested with BglII, HindIII, SacI, XhoI, XbaI, McoI, PvuII, KpnI
or HincII. Blotting and hybridization were done according to
standard procedures.
GenomeWalker Libraries and PCR amplification
GenomeWalker libraries were generated according to the
manufacturer’s instructions (BD Biosciences, Palo Alto, CA,
USA). For the 32-2F53VIII cell line, 2.5 mg of genomic DNA
was digested with PvuII, DraI, StuI or EcoRV. For the 32-7A cell
line, 2 mg of genomic DNA was digested with DraI, EcoRV, PvuII,
ScaI or SspI. Subsequently, the appropriate GenomeWalker
adaptors were ligated to the DNA.
To amplify the segments overlapping the breakpoint, long-
range PCR was done using Takara LA TAQ mix (Takara, Shiga,
Japan) and gene-specific primers GSP1 (59-CCCCTCAGC-
TCTGTGCATTTTGTCTA-39) and GSP2 (59-CCTCTTGCC-
CCCACCTAGTGTTTATTT-39) for the 32-2F53VIII derived
libraries, and primers GSP3 (59-CATAGTGGGGGACATCAT-
GACAGTCAC-39) and GSP4 (59-ACACCACCAGCCTC-
CCTCCATTTCTGA-39) for the 32-7A libraries.
RACE analysis
39RACE was performed with a commercial kit according to the
manufacturer’s instructions (Invitrogen, Merelbeke, Belgium).
Briefly, 2 mg of total RNA isolated from the 32-7A cell line was
reverse transcribed using the Adaptor Primer (AP). Two PCRs
(PCR-A and PCR-B) were set up using the Unabridged Anchor
Primer (UAP) and either GSP1 (59-GCCCTTATGACTCCAAC-
CAG-39) or GSP2 (59-ATTGGCTCATCCTCTCATGTT-39).
Nested PCRs were done using the Abridged Universal Anchor
Primer (AUAP) and GSP2 (for nested PCR on PCR-A), or the
AUAP and GSP3 (59-TCCCAGAAAATGAAAGTGATG-39)
primer pair (nested PCR on PCR-B).
To search for chimeric ACCN1 transcripts, we performed 59 and
39RACE analysis on cDNA from the 32-2F53VIII and 32-7A cell
lines, respectively, using the Generacer kit according to the
manufacturer’s instructions (Invitrogen). Briefly, 2 mg of total
RNA was reverse transcribed using the supplied oligo-dT primer.
In the 39RACE experiment, we performed a PCR with a GSP (59-
AGCACTACAAACCCAAGCAGTTC-39) in combination with
the supplied 39 adaptor primer. Nested PCR was done using a
GSP (59-GTGGGCCATGACCTGAAGGATAT-39) in combina-
tion with the supplied 39 nested primer. In the 59RACE
experiment, we used a GSP (59-CTTGGATGAAAGGTGGCT-
CAGACT-39) together with the supplied 59 adaptor primer.
Nested PCR was performed using a GSP (59-TGATCTC-
CAGCCCGTTGCCTGTC-39) and the supplied 59 nested
primer. Products were cloned in pGEM-T Easy (Promega,
Madison, WI, USA).
mRNA expression profiling by real-time quantitative PCR
For the analysis of the global NBPF expression pattern, we
determined relative gene expression levels using an optimized
two-step SYBR Green I RT-PCR assay employing several
reference genes [19]. After establishment of amplification
efficiencies of .95% for all primer pairs, the delta-Ct method
was used for quantification. SYBR Green I core PCR reagents
were obtained from Eurogentec (Seraing, Belgium) and used
according to the manufacturer’s instructions. Reactions were run
on an iCycler (Bio-Rad, California, USA). Gene expression levels
were normalized using the geometric mean of four reference
genes [19]. Relative expression levels for amplicons in the NBPF
transcripts were measured in a panel of 31 neuroblastoma cell
lines.
For analysis of the NBPF1 expression pattern we determined
the relative gene expression levels by an optimized two-step
SYBR Green I RT-PCR assay using the two most stable
housekeeping genes in neuroblastoma cell lines [19]. One
microgram of total RNA was treated with the RQ1 RNase-free
DNase according to the manufacturer’s instructions (Promega).
Before synthesizing cDNA, treated RNA samples were desalted
on Microcon-100 spin columns (Milipore, Bedford, USA). cDNA
was synthesized at 54uC using gene-specific primers (NBPF1: 59-
CTGGGTGGACTTCGCGTAACTT-39, GAPD: 59-GGCATG-
GACTGTGGTCATGAG-39 and HPRT1: 59-GGTCCTTTTC-
ACCAGCAAGCT-39) and Superscript III reverse transcriptase
according to the manufacturer’s instructions (Invitrogen). RT-
PCR mixes contained 20 ng template cDNA, LightCycler 480
SYBR Green I Mastermix (Roche Diagnostics GmbH, Man-
nheim, Germany) and 900 nM forward and reverse primers.
Reactions were performed on a LightCycler 480 (Roche
Diagnostics) using the following protocol: incubation at 95uC
for 5 min, then 50 cycles at 95uC for 10 sec, 66uC for 30 sec, and
72uC for 1 sec.
Primer sequences for the reference genes are deposited in
RTPrimerDB, a public database for real-time PCR primers
(http://medgen.ugent.be/rtprimerdb/; [20]): UBC, SDHA,
HPRT1, and GAPD. The primer sequences for the NBPF
Neuroblastoma Breakpoint
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amplicons were as follows: amplicon A: 59-GATGAATGTCAG-
GATGCTCTAAACAT-39 and 59-CCACCATGCTGACG-
TTTGTG-39; amplicon B: 59-CAGCAGCACATTTCACTCAT-
TAGAG-39 and 59-TCACTTGATCCCACCGATGTC-39; am-
plicon C: 59-GAGCTGCTGGAGGCAGTAGAG-39 and 59-
GGAGTCAGGCTGTTCAAGACAA-39; amplicon D: 59-
TGGCAACCTGTGCTCAGTCT-39 and 59-GGCATGTG-
CTGCACAGTTATG-39. The primer sequences for the NBPF1
amplicon were 59-GCGAGGCTGCCCGAGCTTCT-39 and 59-
GACTTCGCGTAACTTCCCATTCA-39.
All measurements were performed in triplicates and the mean
Cp-value was used in the calculations. Statistical analysis of the
groups with NBPF1 loss and those without loss was performed with
the Wilcoxon rank sum test.
Cell culture and transfection
The colon cancer cell line DLD1Tr21 Tet-On was obtained
from Van de Wetering et al. [21]. This Tet-On system activates
transcription of the gene of interest in the presence of
doxycycline (Dox). The cells were cultured in RPMI with 10%
fetal calf serum, 100 U/ml penicillin and 100 mg/ml strepto-
mycin. The cDNA for NBPF1-IRES-GFP, fused to an amino-
terminal flag tag, was cloned in the pcDNA4/TO vector
(Invitrogen). This construct was stably transfected in DLD1Tr21
cells using Lipofectamine reagent (Invitrogen) according to the
manufacturer’s instructions. Fluorescence activated cell sorting
allowed rapid isolation of NBPF1-positive cells, and further
subcloning of this population yielded a clone that was more than
90% positive for NBPF1 expression upon induction with Dox
(2 mg/ml, Sigma, Steinheim, Germany) for 48 h. As the
transfected vector encodes a flag-tagged NBPF1 fusion protein,
single colonies were tested for induction of NBPF1 expression
by immunofluorescence staining with the anti-flag antibody
(Sigma).
Colony formation in soft agar
Soft agar assays were performed with 6,500 DLDTr21 cells,
either stably transfected with a GFP-expressing vector or with
the NBPF1-IRES-GFP-expressing vector, both in the presence
and absence of Dox. The cells were cultured in six-well dishes in
a two-layer soft agar system, with 0.7% (w/v) Bacto agar (Difco,
Detroit, MI, USA) on the bottom and 0.35% (w/v) Bacto agar
on the top. Liquid medium was placed on top of the agar.
During incubation, this medium was refreshed every 2 days to
provide a continuous source of Dox. An additional top-agar
overlay was given after one week. Experiments were performed
in duplicates and the mean value was used for further analysis.
Plates were incubated at 37uC with a humidified atmosphere of
5% CO2 for 2 weeks and colonies were counted using an
inverted microscope. Pictures are taken with a Leica microscope
(0.86magnification) or with an Olympus microscope (46mag-
nification).
Ethics
The reported procedures using human samples were fully
approved by the Ethics Committee at Ghent University and
written informed consent was obtained from each patient since
1983. For patients whose DNA was obtained before 1983, only
verbal consent was obtained. Indeed, the Ethics Committee
advised that oral consent was sufficient for those patients, and that
written consent should not be sought because most of these
patients had died, and it was considered more ethical not to raise
the matter with the family members again.
Results
Identification of rearranged genomic fragments
encompassing the constitutional t(1;17) translocation
breakpoint
Karyotypic analysis of the lymphocytes of a neuroblastoma
patient revealed a de novo, constitutional, apparently balanced
translocation between chromosomes 1p36.2 and 17q11.2 [7].
Karyotyping of the primary tumor was unsuccessful, mostly due to
necrosis. Due to the highly repetitive structure of the chromosome
1p36 region, breakpoint cloning proved to be extremely difficult.
For this reason, we constructed a PAC/BAC contig of 1.5 Mbp
covering the 17q breakpoint, and by screening a chromosome-17
specific cosmid library we identified three cosmids overlapping the
breakpoint [18].
To facilitate the identification and cloning of the t(1;17)
translocation breakpoints, genomic DNA from the somatic cell
hybrids 32-7A and 32-2F53VIII, the Chinese hamster ovary
cell line A/3, and normal human placenta were used for
Southern blot analysis. The somatic cell hybrids 32-7A and 32-
2F53VIII contain, respectively, the der(1) and the der(17)
chromosomes of this neuroblastoma patient [7]. Based on the
sequence of the cosmid contig spanning the chromosome 17
translocation breakpoint (GenBank Acc Nu AF148647), nine
DNA probes free of repetitive sequences were selected
(Figure 1A). These probes were used for Southern blot analysis
to search for abnormal, patient-specific hybridization bands.
Probes 6 and 9 revealed additional bands in the DNA of cell
lines 32-2F53VIII and 32-7A, respectively, but not in any of the
other DNAs analyzed, indicating that these fragments span the
chromosome 17 translocation breakpoint (Figure 1B). Both
hybrid cell lines also contain a copy of the normal chromosome
17, resulting in the appearance of a ‘normal’ band in these cell
lines.
Cloning of the constitutional t(1;17) translocation
breakpoints in somatic cell hybrids 32-2F53VIII and 32-7A
We used GenomeWalker PCR to clone the breakpoints of the
der(17) and der(1) chromosomes, present in the somatic cell
hybrids 32-2F53VIII and 32-7A, respectively. For 32-2F53VIII,
we used gene-specific primers (GSP1 and GSP2) localized in the
probe #6 sequence, together with an adaptor-specific primer
(AP1). For 32-7A we used GSP3 and GSP4, localized in or
nearby the probe #9 sequence, together with AP1 and AP2,
respectively.
Cloning from 32-2F53VIII.
Primer pair GSP1 and AP1 was used in a first round of
amplification. Specific products of 1,457 bp and 3,575 bp were
amplified from, respectively, the 32-2F53VIII/StuI and 32-
2F53VIII/PvuII GenomeWalker libraries (Figure 1C). With the
GSP2 and AP1 primer pair, products of 1,029 bp and 3,459 bp
were amplified from, respectively, the 32-2F53VIII/DraI and 32-
2F53VIII/EcoRV GenomeWalker libraries. All four 32-
2F53VIII-specific products were cloned, and complete sequencing
showed overlapping novel sequences derived from chromosome 1
in all clones. In total, we sequenced 3,743 bp flanking the
breakpoint region on the der(17) chromosome, of which 3,134
nucleotides were derived from chromosome 1 (GenBank Acc Nu
AF379607; partly shown in Figure 2A).
Cloning from 32-7A.
Using primer pair GSP3 and AP1, specific products of 1,649
bp and 1,888 bp were amplified from the 32-7A/DraI and 32-
7A/EcoRV GenomeWalker libraries, respectively (Figure 1D).
Neuroblastoma Breakpoint
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Primer pair GSP4 and AP2 amplified products of 1,268 bp and
4,355 bp from, respectively, the 32-7A/SspI and 32-7A/PvuII
GenomeWalker libraries. All four 32-7A-specific products were
cloned, and complete sequencing showed overlapping novel
sequences derived from chromosome 1 in all clones. In total, we
sequenced 4,512 nucleotides, of which 3,845 bp were derived
from chromosome 1 (GenBank Acc Nu AF379606; partly shown
in Figure 2B).
Figure 1. Cloning of the translocation breakpoints of the constitutional t(1;17) translocation. (A) Schematic overview of the sequence of
a cosmid contig spanning the breakpoint [18]. Nine repeat-free probes (white boxes) were used in Southern hybridizations. Recognition sites for PvuII
(P) and EcoRI (E) are shown. (B) Southern blot analysis of genomic DNA of human-hamster cell hybrids containing either the der(1) (hybrid 32-7A) or
the der(17) chromosome (hybrid 32-2F53VIII). Left panel: hybridization of probe 6 to PvuII-digested genomic DNA yielded a band of,4 kbp in the 32-
2F53VIII cell line (arrow) but not in the control samples. Right panel: hybridization of probe 9 to EcoRI-digested genomic DNA showed an additional
band of,17 kbp in the 32-7A cell line (arrow) but not in the control sample. A/3: parental hamster cell line; normal: normal human genomic placenta
DNA. (C) Schematic overview of a fragment of derivative chromosome 17. Two primers located in probe 6 (GSP1 and GSP2) were used in combination
with adaptor primers to amplify breakpoint-spanning fragments from genomic DNA digested with BamHI (B), DraI (D), EcoRV (EV), PvuII (P) or StuI (S).
All the resulting fragments contained sequences derived from chromosome 1, with an overlap of 3,134 bp. Seven nucleotides of unknown origin are
inserted at the breakpoint site. The location of the t(1;17) translocation breakpoint is indicated by a vertical double-pointed arrow. White boxes
represent chromosome 17 sequences, and black boxes represent chromosome 1 sequences. (D) Schematic overview of a fragment of derivative
chromosome 1. Two primers located in or nearby probe 9 (GSP3 and GSP4, respectively) were used in combination with adaptor primers to amplify
breakpoint-spanning fragments from genomic DNA digested with DraI (D), EcoRV (EV), PvuII (P) or StuI (S). All the resultant fragments contained
sequences derived from chromosome 1, with an overlap of 3,845 bp. Four nucleotides of unknown origin are inserted at the breakpoint site. The
translocation breakpoint and sequences are indicated as in panel (C).
doi:10.1371/journal.pone.0002207.g001
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Analysis of sequences flanking the constitutional t(1;17)
translocation breakpoints
Previous FISH experiments indicated that the constitutional
translocation was balanced [7]. To verify this at the molecular
level, we compared the chromosome 17 sequences obtained by
GenomeWalker PCR to the sequence of the cosmid contig
spanning the der(17) translocation breakpoint. We found that the
translocation was indeed balanced on this level (Figure 2C).
However, comparison of the chromosome 1 sequences to the
human genome reference sequence (NCBI Build 36.1) revealed
greater complexity.
In both derivative chromosomes, a few nucleotides of unknown
origin had been inserted between the chromosome 1 and
chromosome 17 sequences (Figures 1 and 2), a feature frequently
observed in reciprocal constitutional translocations [22]. Remark-
ably, both the chromosome 1 translocation breakpoint cloned
from the der(1) chromosome and the chromosome 17 breakpoint
were located in LINE repeats (Figure 3). The repeat on
chromosome 1 had been classified as type L1-PA4 [23], and the
LINE repeat on chromosome 17 as type L2. However, when we
compared these two LINE repeats, no significant sequence
homology was found. On the other hand, the chromosome 1
breakpoint cloned from the der(17) chromosome was located in a
repeat-free region.
We previously reported that ACCN1 is the closest gene to the
17q breakpoint [18], but after completion of the human genome
sequence it became clear that the translocation disrupts one of the
isoforms of ACCN1 (Figure 3). This gene encodes an amiloride-
sensitive cation channel [24] with two transmembrane domains
[25]. It was shown that the ACCN1 gene is expressed as two
isoforms differing in their 59UTR and N-terminal domain
(Figure 3) [26]. All exons encoding isoform 1 (GenBank Acc Nu
NM_183377.1) are located proximal to the translocation break-
point, whereas the first exon of isoform 2 (GenBank Acc Nu
NM_001094.4) is located distal to the breakpoint. The remaining
exons of isoform 2 are shared with isoform 1 and are proximal to
the breakpoint. The translocation thus disrupts isoform 2 of the
ACCN1 gene without disturbing isoform 1 (Figure 3). Both isoforms
are also found in mouse and rat, strengthening their functional
relevance. On the translocated 1p-fragment of the der(17)
chromosome, we identified three exons encoding the carboxy-
terminal domain of the recently described NBPF1 protein. These
are shown as exons of types 11, 12 and 14 in figures 1C and 3 (see
[27] for numbering of NBPF1 exon types). NBPF1 is a member of a
novel gene family with an intricate genomic structure [27–29].
Analysis of the der(1) sequences proximal to the breakpoint
revealed the presence of two exons (shown as exons of types 6 and
7 in Figure 1D and Figure 3) that encode an internal domain of
the NBPF1 protein. From this we conclude that the two
breakpoints are located within distinct introns of the NBPF1 gene.
Although the translocation appeared cytogenetically balanced,
molecular cloning of the breakpoint sequences revealed a deletion
of part of the NBPF1 gene. Recent reports describing structural
variation in the human genome have shown recurrent structural
abnormalities in the NBPF1 locus in normal individuals [30,31];
we also observed these abnormalities in our analysis of NBPF1
cDNA clones [27]. Due to this diversity, it is not possible to
precisely determine the length of the deleted genomic fragment on
chromosome 1 in this patient. However, compared to the human
genome reference sequence (NCBI Build 36.1), a fragment
comprising at least four exons of the NBPF1 gene is missing
(5,215 bp nucleotides: 16,764,933 to 16,770,147 of chromosome
1).
Chimeric transcripts resulting from the translocation
Chromosomal translocations within a gene can generate one or
two chimeric genes with altered functions. The two open reading
frames disrupted in the t(1;17) translocation are encoded by
complementary DNA strands, ruling out the possibility of chimeric
NBPF1-ACCN1 transcripts (Figure 3). To isolate other chimeric
cDNAs resulting from the t(1;17) translocation, we performed
RACE (Rapid Amplification of cDNA Ends) analyses on the two
hybrid cell lines, each of which contained one of the derivative
chromosomes.
We amplified two chimeric NBPF1 transcripts in the 32-7A cell
line (Figure 3). In one chimeric transcript, the type-7 exon
sequence was spliced to chromosome-17 sequences located 338 bp
distal to the breakpoint, yielding a transcript extended by 295
nucleotides derived from chromosome 17, and an open reading
frame extended by 34 additional codons (GenBank Acc No.
AF420438). In a second chimeric transcript, the type-7 exon
sequence was spliced to chromosome-17 sequences located 8,602
bp from the breakpoint, yielding a transcript extended by 325
nucleotides derived from chromosome 17, and an NBPF1 open
reading frame extended by 11 additional codons (GenBank Acc
Nu AF420439). The sequences derived from chromosome-17 were
not found in other sequences known to be expressed, and were
therefore classified as non-expressed sequences. An in silico analysis
of the chimeric proteins encoded by these transcripts did not reveal
any other identifiable domains.
For ACCN1, we were unable to detect any chimeric cDNAs in
the two hybrid cell lines containing the derivative chromosomes.
Expression profiling in neuroblastoma cell lines and
tumors
A typical feature of a classical TSG is that its function is
inactivated in different tumors. This inactivation can be caused by
lack of expression due to deletion or promoter silencing. In a first
quantitative RT-PCR assay we assessed four amplicons distributed
across the NBPF transcripts (Figure 4A, top panel). This allowed us
to define the expression profile of the complete NBPF gene family in
neuroblastoma cell lines, as the primers we used bind to regions that
show high sequence identity between the different NBPF paralogs.
Additionally, due to the repetitive nature of the NBPF genes [27],
Figure 2. Cloning of the constitutional t(1;17) translocation
breakpoints in the cell hybrids 32-2F53VIII and 32-7A.
Nucleotide sequences of the der(17) (A) and der(1) (B) regions flanking
the translocation breakpoints. (C) Compilation of normal and derivative
sequences at the breakpoint sites (NCBI Build 36.1) showing complete
preservation of chromosome 17 sequences but not of chromosome 1
sequences.
doi:10.1371/journal.pone.0002207.g002
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some primers can also bind to multiple positions on one transcript.
We chose two amplicons that occur only once in a single NBPF
transcript: on exon types 8-9 (amplicon B) and on the 39 UTR
(amplicon D). In addition, we used two amplicons that can occur in
multiple copies in the same transcript: one amplicon on the 59
repeat exons (amplicon A) and one amplicon on the 39 repeat exons
(amplicon C). In the reference NBPF1 transcript (GenBank Acc Nu
NM_017940), amplicon A is present in two copies and amplicon C
as one copy (Figure 4A). However, in transcripts from other NBPF
paralogs, amplicon A can be present as only one copy and amplicon
C can be present as multiple copies [27]. These amplicons were
analyzed in a panel of 31 neuroblastoma cell lines, some with a
heterozygous deletion of NBPF1 (n = 25) and some with two copies
of the NBPF1 gene (n= 5). As expected, the expression levels of
amplicons B and D were comparable (Pearson correlation
coefficient 0.95), but in some cases these levels differed considerably
from those of amplicons A and C (Pearson correlation coefficient
0.86 for both A–D and C–D). All together, this analysis showed that
the expression of all NBPF transcripts combined varied widely
between different neuroblastoma cell lines: expression of amplicon
C in cell lines SK-N-FI, SK-N-SH and NLF was up to fifteen-fold
higher than in STA-NB-3. However, the expression level of
amplicon B in these three cell lines was only six- to eleven-fold
higher than in STA-NB-3. This difference was probably due to
increased expression of transcripts containing multiple copies of
amplicon C (e.g. NBPF10) [27] in the SK-N-FI, SK-N-SH and NLF
cell lines as compared to STA-NB-3.
For all amplicons, the median expression level of the NBPF
family for cell lines with NBPF1 loss was lower than for cell lines
with a normal 1p chromosome (Figure 4B). For amplicons A, B
and D, the difference was statistically significant (p,0.05) but for
amplicon C it was not (p=0.13). Moreover, meta-analysis using
the Oncomine database [32] revealed a significantly lower
expression level of NBPF transcripts in neuroblastomas that
relapsed within five years than in those that did not relapse
(Figure 4C) [33].
The abovementioned primers amplified all NBPF transcripts,
but the constitutional translocation disrupted only the NBPF1
Figure 3. Genomic overview of the translocation breakpoints of the der(1) and der(17) chromosomes. Schematic representation of the
normal chromosome 1p36 and 17q12 regions is shown in the central box. On chromosome 1 (black bars) both translocation breakpoints are located
in intronic regions of the NBPF1 gene, which is only partially shown (indicated by the dotted line). The breakpoint of the der(1) chromosome is
located in a LINE repeat, shown as a black box labeled L1-PA4 on the genomic region. The black boxes below the genomic sequence represent the
exons of the NBPF1 gene, with the exon type [27] indicated under each box. The translocation resulted in deletion of 5,215 bp. The translocation
breakpoint on chromosome 17 (white bars) is located in an ACCN1 intron and disrupts isoform 2 but leaves isoform 1 intact. Transcription starts are
indicated by angled arrows. The breakpoint is located in a LINE repeat, shown as a white box labelled L2 on the genomic region. White boxes below
the genomic sequence represent the exons of the ACCN1 gene. On the der(1) chromosome (top), the NBPF1 gene is disrupted, giving rise to two
chimeric cDNAs (shown as NBPF1-CHI, with the grey box representing the chromosome 17-derived fusion partners). The promoter region and first
exon of ACCN1 isoform 2 are translocated to the der(1) chromosome, but no chimeric transcripts have been isolated yet (shown with the question
mark and dotted line). On the der(17) chromosome (bottom), ACCN1 isoform 1 is unaffected by the translocation, but as the promoter and first exon
of isoform 2 are translocated, isoform 2 is probably no longer expressed (shown by the dotted line and question mark). The last three NBPF1 exons
(shown as exons of types 11, 12, and 14) are translocated to the der(17) chromosome. Arrows on the genomic sequence represent promoter
sequences, and arrowheads in the transcripts show the orientation of the genes; tel, telomeric end; cen, centromeric end. The figure is not drawn to
scale.
doi:10.1371/journal.pone.0002207.g003
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Figure 4. Expression analysis of the NBPF gene family in neuroblastoma cell lines and tumors. (A) Real-time quantitative RT-PCR analysis
of the NBPF gene family in a panel of neuroblastoma cell lines. Four different amplicons on the NBPF cDNA were chosen, of which A and C can have
several copies in a single NBPF transcript [27]. The top panel shows the location of these amplicons in the standard NBPF1 transcript. Amplicon A is
present in two copies in this particular transcript. Expression levels were normalized to four reference genes [19], and the lowest value was set to 1.
(B) Neuroblastoma cell lines were grouped according to the NBPF1 status (heterozygous NBPF1 deletion or not). For all amplicons, this resulted in a
Neuroblastoma Breakpoint
PLoS ONE | www.plosone.org 7 May 2008 | Volume 3 | Issue 5 | e2207
gene, so we also determined the expression profile of this gene
specifically. We designed primers located on the 59 UTR of the
NBPF1 gene, where it has slightly lower sequence homology with
the other NBPF paralogs. Specific NBPF1 amplification was
determined by melting curve analysis, which showed a single
peak, and by sequence analysis of the amplicon. The expression
level of NBPF1, determined for a panel of 32 neuroblastoma cell
lines, varied widely between the different samples (Figure 5), like
it did in the expression analysis of the total NBPF family.
Interestingly, we did not observe complete loss of NBPF1
expression in any cell line, as has been described for other genes
located in the 1p36 region [16,17]. Statistical analysis of these
data with the Wilcoxon rank sum test revealed a significantly
lower expression level of NBPF1 in cell lines with a heterozygous
deletion of the NBPF1 locus compared to cell lines without
NBPF1 loss (p,0.05).
Our analysis of ACCN1 (Figure 6) was limited to meta-analysis
using the Oncomine database [32]. We observed a significantly
weaker expression of ACCN1 in neuroblastomas with MYCN
amplification (p,0.01) [34] or with 1p36 loss of heterozygosity
(p,0.01) [34] compared to tumors without these alterations.
Additionally, weaker ACCN1 expression was correlated with higher
stages of disease (p,0.01) [33]. On the other hand, no difference
was observed between neuroblastomas with or without 11q23 loss
of heterozygosity (LOH) (p=0.10) [34].
NBPF1 expression suppresses anchorage-independent
growth
The DLD1Tr21 cell line is a human colon cancer cell line
expressing high levels of the tetracycline repressor protein,
resulting in a tight control of the expression of the gene of interest
under control of a responsive tetracycline operator element [21].
This reliable cell system was stably transfected with an expression
vector harboring an inducible flag-tagged full length NBPF1. As
shown in Figure 7A, the addition of doxycyclin (Dox) to the cell
cultures for 48 h resulted in the expression of NBPF1 in the
cytoplasm of the cells.
To determine whether overexpression of NBPF1 influences
anchorage-independent growth, we compared the ability of
DLD1Tr21/mock and DLD1Tr21/NBPF1 cells to form colonies
in soft agar in the absence and presence of Dox. NBPF1-
expressing cells formed significantly fewer colonies than the
control cell lines or the non-induced DLD1Tr21/NBPF1
(figures 7B and 7C). These data indicate that overexpression of
NBPF1 strongly inhibits the ability of this human cancer cell line
to form colonies in soft agar.
Figure 5. Expression analysis of NBPF1 in a panel of 32 neuroblastoma cell lines. Expression levels were normalized to two reference genes
[19], and the lowest value was set to 1. Inset: relative expression levels of NBPF1 in neuroblastoma cell lines with normal NBPF1 status (grey; NO) or
with a heterozygous deletion of the NBPF1 locus (white; YES). Significantly lower NBPF1 expression is observed in cell lines with NBPF1 loss (p,0.05).
doi:10.1371/journal.pone.0002207.g005
median expression level that was lower in cell lines with NBPF1 loss, and this difference was significant for amplicons A, B and D (p,0.05), but not for
amplicon C (p=0.13). (C) Meta-analysis of the NBPF expression level in neuroblastoma tumors using the Oncomine database [32]. The reporter used
in the array experiment was derived from NBPF1, but due to the high sequence identity among the NBPF paralogs, this analysis also represents the
expression level of all NBPF genes. Significantly lower levels of NBPF transcripts are observed in tumors that relapse within five years.
doi:10.1371/journal.pone.0002207.g004
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Discussion
Constitutional chromosomal abnormalities in patients bearing
specific tumors have often been used to clone new TSGs. Here, we
describe the breakpoint cloning of a constitutional translocation
t(1;17)(p36.2;q11.2) present in a neuroblastoma patient. Aberra-
tions in the chromosomal regions involved in this translocation are
recurrent in neuroblastoma, and so we hypothesized that this
translocation predisposed the patient to the development of
neuroblastoma. We cloned both translocation breakpoints and
identified on chromosome 1 a novel gene that is interrupted by the
translocation. This gene is a member of the recently described
NBPF gene family, which comprises 22 genes with highly repetitive
exon types [27–29]. As these genes are located in regions of
segmental duplications on chromosome 1, they show high
sequence homology in both coding and non-coding regions.
Unbalanced translocations between chromosomes 1 and 17 are
common in neuroblastomas, but currently it is unclear whether
there is a link between these somatic translocations and the
constitutional balanced translocation described here. Only a few of
the translocation breakpoints have been cloned [35,36], and no
unifying underlying mechanisms for the translocations have been
proposed. Two groups reported increased frequency of chromo-
some 11q translocations in regions of segmental duplications
[37,38]. In this respect, is striking that the chromosome 1
breakpoint in the t(1;17) translocation described here is also
localized in a region of segmental duplication.
NBPF1 is located on human chromosome 1p36. Though it is
located outside of the smallest region of overlap defined by a large-
scale analysis of neuroblastoma tumors [15], at least one copy of
the region encompassing the NBPF1 gene is deleted in most
neuroblastomas with 1p deletion. Tumor material from the
neuroblastoma patient with the constitutional translocation was
not available for genetic analysis, so we cannot exclude the
possibility that the der(17) was lost in the tumor, leading to loss of
the 1p segment distal to the translocation breakpoint. All genes
located distal to the NBPF1 gene would therefore show LOH in
the tumor, including a number of recently identified TSGs located
in this region [13,14]. Alternatively, as our NBPF1 expression
profiling revealed a decreased expression in neuroblastoma cell
lines with a heterozygous deletion of the NBPF1 locus, it is also
possible that NBPF1 acts as a haploinsufficient gene. The
expression pattern of NBPF1 is reminiscent of the expression
analysis of other genes located in the 1p35-36 region, where 15–
20% of the genes showed a lower expression level in neuroblas-
toma tumors and cell lines with 1p loss of heterozygosity [17,39]. It
has been proposed that the combined diminished expression of
these genes, rather than the inactivation of one single classical
TSG, could cause the unfavorable outcome associated with 1p
deletions in neuroblastoma. In addition to analyzing specifically
the NBPF1 gene, we also analyzed the complete NBPF gene family
in neuroblastoma cell lines; most amplicons showed a significantly
lower expression level in neuroblastoma cell lines with NBPF1 loss.
In these cell lines the deletion was limited to NBPF1 and NBPF3,
and the other NBPF members, located on chromosome 1q21,
apparently cannot fully compensate for the decreased expression
of the two deleted NBPF genes. Our qRT-PCR analyses were
complemented by a meta-analysis using the Oncomine database
[32]. These analyses showed decreased NBPF levels in neuroblas-
tomas that relapsed within five years. During our previously
reported analysis of the NBPF family, we detected structural
variation in the NBPF1 gene in different individuals [27]. Similar
results were reported in large-scale studies investigating copy-
number variation between people [30]. These structural variants
of NBPF1 and its paralogs should be taken into consideration when
choosing amplicons and analyzing the expression levels of these
genes in different cell lines.
Furthermore, expression of NBPF1 in a human colorectal cell
line severely suppressed soft agar colony formation, demonstrating
Figure 6. Oncomine expression analysis of ACCN1 in neuroblastoma tumors. Significantly weaker ACCN1 expression is observed in tumors
with MYCN amplification (MNA), in higher stage tumors (stage 3+4), and in tumors with 1p36 loss of heterozygosity (1p36 LOH), but not in tumors
with 11q23 LOH.
doi:10.1371/journal.pone.0002207.g006
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that NBPF1 might act as a TSG, at least in colon cancer. So far,
technical difficulties have prevented us from testing this hypothesis
in neuroblastoma cell lines. As colorectal cancer is also
characterized by frequent deletions or translocations of 1p36
[11], we believe that our present data is a first step in the
elucidation of the potential tumor suppressive properties of
NBPF1. The underlying mechanism for this NBPF1 activity is
currently unknown.
ACCN1 encodes an amiloride-sensitive cation channel and can
be expressed as two different isoforms differing in their
aminoterminal domains [26]. The constitutional translocation in
the present patient truncates the longer isoform. Interestingly,
restoration of surface expression of this isoform in glioma cells
reduces cell growth and migration [40], classifying it as a potential
tumor suppressor. Meta-analysis of ACCN1 expression in neuro-
blastomas showed a correlation between 1p36 LOH and
decreased levels of ACCN1, but no such correlation was observed
between 11q23 LOH and the expression level of ACCN1 [34].
LOH of 1p36 and of 11q23 are both associated with high-risk
disease, but only 1p36 LOH is associated with MYCN amplifica-
tion [6]. Another report showed a decreased expression level of
ACCN1 in neuroblastomas with high telomerase activity [41].
Knockout mice defective in both ACCN1 isoforms were viable,
fertile, and showed no morphological or behavioral abnormalities,
but did indicate that ACCN1 has a role in retinal function [42]. No
data have been reported on tumor incidence or tumor
aggressiveness in these mice. The most frequent chromosomal
abnormality in neuroblastomas is gain of chromosome 17 [43],
which appears to conflict with a potential tumor suppressor
function for ACCN1 in neuroblastoma. However, most 17q
Figure 7. Induced expression of NBPF1 in human tumor cells impairs colony formation in soft agar. (A) DLD1Tr21/NBPF1 cells express
flag-tagged NBPF1 in the cytoplasm, but only when Dox is added to the medium (left panels). DAPI staining was used to visualize nuclei (right
panels). (B) DLD1Tr21/NBPF1 and DLD1Tr21/Mock cells were seeded in soft agar in six-well plates in the absence or presence of Dox and then
incubated for 2 weeks. NBPF1 induction induces a severe decrease in the ability to form colonies on soft agar. Pictures in the top panel were taken at
a 0.86magnification and those in the bottom panel at a 46magnification. Scale bars indicate 200 mm. (C) Quantification of the soft agar colonies
(mean6standard deviation for two experiments). Only colonies larger than 100 mm were counted. Induction of NBPF1 expression by adding Dox
results in a severe decrease in the number of colonies in comparison to the control setting (Mock) or the non-induced (-Dox) cells.
doi:10.1371/journal.pone.0002207.g007
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breakpoints are distal to ACCN1, and it has been suggested that the
17q12 region might contain a gene that suppresses neuroblastoma
[44]. These data warrant further investigation into the role of
ACCN1 in neuroblastoma. Additionally, it remains possible that
the translocation analyzed here affects an unidentified gene in the
ACCN1 intron in which the translocation breakpoint lies. In this
region we observed two putative promoter sequences, as predicted
by FirstEF [45], and a small number of ESTs not annotated to a
known gene and devoid of a meaningful open reading frame (data
not shown). It is not clear whether these sequences have a function
or are merely the result of random transcriptional activation.
In conclusion, we describe the molecular cloning of both
translocation breakpoints in a neuroblastoma patient with a
constitutional t(1;17) translocation. Genes overlapping both
translocation breakpoints were identified, namely NBPF1 on
chromosome 1 and ACCN1 on chromosome 17. Further research
might reveal the role of the disruption of both of these genes in the
development and progression of neuroblastoma.
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